Indian Pharma in September 2025: Momentum, Disruption & Caution

By Anup Soans

October 8, 2025

By MedicinMan Editorial Team
Published: October 2025

💊 Introduction

September 2025 marked a turning point for India’s pharmaceutical industry. The market continued to grow in value despite regulatory tremors, safety controversies, and global trade pressures. On the brighter side, innovation and chronic-care therapies kept fueling demand, signaling long-term resilience.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences

Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore

Indian Pharma in September 2025: Momentum, Disruption & Caution

💊 Introduction

Free Membership Required

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Topics

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

A Tale of Two Cities: Peptides and Prescriptions

Trust Is Pharma’s Fulcrum: Are We Getting the Basics Right?

The $1.5 Billion Question in Hyderabad: Orbicular, Peptides and the PE Re-Rating of Indian Complex Generics

Medical Reps—Lessons From The West: The Old Model is Dead

Related Articles

What’s Killing Patients? Cancer or Rigged Drug Prices?

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Company

Headlines

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

The Rx–Outcomes Dichotomy: India Has Iron Tablets. Why Does Anaemia Persist?

10 Years of Pharma M&A — Who’s Really Benefited?

What’s Killing Patients? Cancer or Rigged Drug Prices?

Newsletter